Durable response in platinum refractory small cell carcinoma of the ovary hypercalcemic type treated with combination pembrolizumab, oral cyclophosphamide, and bevacizumab

Int J Gynecol Cancer. 2024 May 6;34(5):777-782. doi: 10.1136/ijgc-2024-005321.
No abstract available

Keywords: Adnexal Diseases; Ovarian Diseases; Ovarian Neoplasms; Ovary.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bevacizumab* / administration & dosage
  • Carcinoma, Small Cell* / drug therapy
  • Carcinoma, Small Cell* / pathology
  • Cyclophosphamide* / administration & dosage
  • Female
  • Humans
  • Hypercalcemia / drug therapy
  • Middle Aged
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / pathology

Substances

  • Bevacizumab
  • Cyclophosphamide
  • Antibodies, Monoclonal, Humanized
  • pembrolizumab